Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 12;17:1121–1127. doi: 10.2147/OPTH.S401743

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Jiang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Effects of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on retinal tissue perfusion (A) RTP and blood flow (B) RBF in mild diabetic retinopathy patients with methylenetetrahydrofolate reductase polymorphisms (DR + PM) patients receiving the medical food during follow-up periods. In patients with A1298C mutation, all vascular metrics (including RTP and RBF) were improved over the Baseline at 4 months and 6 months, but the peak benefit was at four months (all P < 0.05). In patients with C677T and C677T/A1298C compound mutations, RTP at 6 months significantly increased as compared to those at baseline and 4 months. Bars = standard error.